Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 365 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2004  |  Volume : 6  |  Issue : 2  |  Page : 60-62

Treatment Of Osteoporosis - Why, Whom, When And How To Treat


Correspondence Address:
E Seeman


Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

The rigorously investigated drugs reported to reduce vertebral fractures are alendronate, risedronate, raloxifena and PTH HRT is no longer first choice for fracture prevention given the risk for adverse events, even though these risks are small. Evidence supporting the use of calcitonin, fluoride, anabolic steroids, active vitamin D metabolites is inadequate. The rigorously investigated drugs reported to reduce non-vertebral fractures are the two bisphosphonates and PTH. Evidence for anti-hip fracture efficacy is confined to the two bisphosphonates. Calcium and vitamin D and hip protectors have been reported to reduce hip fractures in institutionalized elderly. Women and men with fragility fractures should be treated with agents that have been thoroughly investigated.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed432    
    Printed28    
    Emailed0    
    PDF Downloaded114    
    Comments [Add]    

Recommend this journal